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Context: Polymorphisms in the gene encoding the glu-
cocorticoid receptor (GR) regulating co-chaperoneFKBP5
have been shown to alter GR sensitivity and are associ-
ated with an increased risk to develop posttraumatic stress
disorder (PTSD).
Objective: To investigate interactions of the FKBP5
single-nucleotide polymorphism rs9296158 and PTSD
symptoms on baseline cortisol level, low-dose dexameth-
asone suppression, and whole-blood gene expression.
Design: Association ofFKBP5 genotypes and PTSD symp-
toms with endocrine measures and genome-wide expres-
sion profiles.
Setting: Waiting rooms of general medical and gyneco-
logical clinics of an urban hospital at Emory University.
Participants: The 211 participants were primarily Afri-
can American (90.05%) and of low socioeconomic sta-
tus and had high rates of trauma and PTSD.
Main Outcome Measures: Baseline and post–
dexamethasone suppression cortisol measures and gene
expression levels.
Results: In our endocrine study, we found that only risk
allele A carriers of rs9296158 showed GR supersensitiv-
ity with PTSD; in contrast, baseline cortisol levels were
decreased in PTSD only in patients with the GG geno-
type. Expression of 183 transcripts was significantly cor-
related with PTSD symptoms after multiple testing cor-
rections. When addingFKBP5 genotype and its interaction
with PTSD symptoms, expression levels of an addi-
tional 32 genes were significantly regulated by the inter-
action term. Within these 32 genes, previously reported
PTSD candidates were identified, including FKBP5 and
the IL18 and STAT pathways. Significant overrepresen-
tation of steroid hormone transcription factor binding sites
within these 32 transcripts was observed, highlighting
the fact that the earlier-described genotype and PTSD-
dependent differences in GR sensitivity could drive the
observed gene expression pattern. Results were vali-
dated by reverse transcriptase–polymerase chain reac-
tion and replicated in an independent sample (N=98).
Conclusions: These data suggest that the inheritance of
GR sensitivity–moderating FKBP5 polymorphisms can
determine specific types of hypothalamic-pituitary-
adrenal axis dysfunction within PTSD, which are also re-
flected in gene-expression changes of a subset of GR-
responsive genes. Thus, these findings indicate that
functional variants in FKBP5 are associated with biologi-
cally distinct subtypes of PTSD.
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P OSTTRAUMATIC STRESS DISOR-der (PTSD) is a severelydebilitating psychiatric con-dition characterized by per-sistent symptoms of intru-
sive reexperiencing, avoidance, and
hyperarousal following exposure to a trau-
matic event. Although a lifetime trauma
incidence of 40% to 90% in the general
population has been reported, the overall
lifetime prevalence for PTSD ranges be-
tween 7% and 12%.1,2 This suggests that
individuals with a specific genetic suscep-
tibility might have a higher risk of devel-
oping PTSD after experiencing traumatic
events. Twin and family studies have pro-
vided evidence for a genetic component
in the development of PTSD.3-5
While studies investigating main ge-
netic effects associated with PTSD have
yielded inconsistent findings,6-8 there is
growing evidence supporting the role of
geneenvironment interactions in PTSD.9
For example, polymorphisms in the sero-
tonin transporter gene as well as in the
glucocorticoid receptor–regulating co-
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chaperone FK506 binding protein 5 (FKBP5) have been
found in more than 1 cohort to have significant interac-
tions with environmental exposure on risk for PTSD.9-11
Additionally, the syndrome of PTSD, as with many other
psychiatric disorders, is clinically variable. The identifi-
cation of biologically distinct subsets of patients with PTSD
would provide an important tool for improving our
mechanistic, diagnostic, and therapeutic approaches to
PTSD. This study is predicated on the possibility that there
are subtypes of PTSD that can be differentiated based on
differential physiological stress reactivity that may, in part,
be genetically determined.
The stress hormone system, or hypothalamus-pituitary-
adrenal (HPA) axis, is likely an important mediator of
such geneenvironment interactions because it is acti-
vated by traumatic events and dysregulated in a number
of psychiatric disorders, including PTSD.12 In fact, HPA
axis dysfunction with higher glucocorticoid receptor (GR)
sensitivity is described to be one of the endocrine hall-
marks of PTSD.13 A number of studies have shown al-
tered stress hormone/cortisol levels in PTSD and en-
hanced GR sensitivity as measured by a low-dose
dexamethasone suppression test as well as ex vivo bind-
ing assays.14-17
Overall, these studies reflect a sensitization of the HPA
axis in response to exposure to stressors, with changes
in GR function playing a critical role in the pathophysi-
ology of PTSD. The function of the GR is dependent on
a large molecular complex, including chaperones and co-
chaperones as well as coactivators and corepressors.18,19
One of the co-chaperones strongly regulating GR func-
tion is FKBP5, which is part of the mature GR hetero-
complex and is known to regulate GR sensitivity.20 When
bound to the steroid receptor, FKBP5 decreases its af-
finity for the ligand and prevents translocation to the
nucleus.20,21 By being a modulator of GR sensitivity,FKBP5
is an interesting candidate gene for PTSD. In fact, 2 stud-
ies so far have reported interactions of functional poly-
morphisms within FKBP5 with early trauma to predict
adult PTSD.10,11 In addition to these interaction effects
on PTSD symptoms, we have also reported FKBP5 geno-
type–dependent difference in GR sensitivity in PTSD.10
Only patients with PTSD carrying the risk alleles dis-
played increased GR sensitivity, suggesting that endo-
crine changes observed with PTSD might be restricted
to a genetically defined subset of patients.
In our previous report, rs9296158 showed the stron-
gest interaction with early trauma on PTSD symptoms10
and was chosen as a tagging single-nucleotide polymor-
phism (SNP) for a functional haplotype that includes
rs1360780 and rs3800373. Within this haplotype, risk
alleles for PTSD are associated with an increased induc-
tion of FKBP5 messenger RNA by glucocorticoids, in-
creased FKBP5 protein levels, and, as a consequence, a
decrease in GR sensitivity and negative feedback regu-
lation of the HPA axis in healthy controls.10,22,23 Genotype-
dependent endocrine and messenger RNA effects in PTSD
are less well studied.
We hypothesized that functional polymorphisms
within FKBP5 are associated with differential GR sensi-
tivity, which together may define biologically distinct sub-
sets of patients with PTSD. To test this, we investigated
interactions of the FKBP5 SNP rs9296158 and PTSD
symptoms on baseline cortisol level, low-dose dexameth-
asone suppression, and whole-blood gene expression in
a highly traumatized, low-income, primarily African
American cohort with high rates of PTSD.24,25
METHODS
SAMPLES
The participants were a subset of a larger study investigating
the contribution of genetic and environmental factors in
PTSD10,25,26 and they had each experienced at least 1 traumatic
event. Individuals were recruited between 2007 and 2010 at
Grady Memorial Hospital, Atlanta, Georgia.24 All study proce-
dures were approved by the institutional review boards of Emory
University School of Medicine and Grady Memorial Hospital
and all subjects gave written informed consent to the study.
Of the 219 participating individuals, 211 had available se-
rum samples for baseline cortisol level only, while 115 also had
cortisol measures after low-dose dexamethasone suppression.
All individuals had DNA samples from whole blood or saliva
and whole-blood RNA. Of 219 individuals, 10 samples were
excluded from RNA analysis because of a low RNA integrity
number (5.0).27 Of 209 individuals, 111 individuals served
as discovery samples and 98 served as replication samples for
gene expression (eFigure 1 and eTable 1, http://www
.archgenpsychiatry.com).
PSYCHOLOGICAL ASSESSMENTS
PTSD Symptom Scale
The PTSD Symptom Scale (PSS) was used as a measure of PTSD
symptoms.28 The PSS frequency items were summed to obtain
a continuous measure ranging from 0 to 48. The mean (SD)
PSS score across all 219 individuals was 13.12 (12.33) points,
with values more than 20.0 usually considered to show clini-
cally significant PTSD symptoms. Application of the DSM-IV
criteria for PTSD to the PSS frequency items was used to cre-
ate a proxy variable for PTSD diagnosis status.
Clinician-Administered PTSD Scale
The Clinician-Administered PTSD Scale (CAPS) score was avail-
able for a subset of 156 of the 219 individuals.29 The mean (SD)
current CAPS score in the 156 individuals was 39.95 (40.38).
There was a significant correlation between PSS score and cur-
rent CAPS score (Pearson r=0.657; P .01).
Beck Depression Inventory
The Beck Depression Inventory was administered to measure
depression symptoms.30 In this sample, the Beck Depression
Inventory score ranged from 0 to 55 (mean [SD], 14.26 [11.63]).
Values more than 18.0 are considered to show clinically rel-
evant depressive symptoms.
TRAUMA EXPOSURE MEASUREMENTS
Trauma Events Inventory
The Trauma Events Inventory was the primary measure of non–
child abuse trauma in this study.31 Total numbers of different
types of non–child abuse trauma among the participants were
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summed. The mean (SD) score for non–child abuse trauma re-
ported within this study sample was 3.90 (2.61).
Childhood Trauma Questionnaire
The Childhood Trauma Questionnaire was used as a continu-
ous measure of child abuse.32 The Childhood Trauma Ques-
tionnaire score ranged from 25 to 111, with a mean (SD) of
42.20 (18.59).
Substance Abuse
Open-ended questions as well as the Kreek-McHugh-Schluger-
Kellogg Scale were used to quantify self-exposure to opiates,
cocaine, alcohol, and tobacco33 and to assess overall current and
past substance use.
Dexamethasone Suppression Test
The subjects were characterized using a low-dose dexameth-
asone suppression test. After patients fasted, blood was col-
lected between 8 and 9 AM for baseline serum cortisol mea-
surements. The subjects received 0.5 mg of dexamethasone orally
at 11 PM. Blood was collected between 8 and 9 AM the next day
for serum cortisol measurement after dexamethasone stimu-
lation. Serum cortisol concentration was measured with a com-
mercial radioimmunoassay kit (Diagnostic Systems Laborato-
ries, Webster, Texas).
DNA Extraction and SNP Genotyping
DNA was extracted from whole blood or saliva collected in Ora-
gene saliva kits (DNA Genotek, Ottawa, Ontario, Canada) using
the Qiagen M48 automated extraction system (Qiagen, Valen-
cia, California). We genotyped rs9296158 using a TaqMan-
based assay, as described before.10
RNA Extraction and Microarray Procedures
for the Atlanta PTSD Samples
After patients fasted, whole blood was collected between 8 and
9 AM in Tempus RNA tubes (Applied Biosystems, Darmstadt,
Germany) for baseline cortisol measurements. RNA was iso-
lated using the Versagene kit (Gentra Systems, Minneapolis,
Minnesota) and quantified using the NanoPhotometer (Im-
plen, Westlake Village, California) and quality checks were per-
formed on the Agilent Bioanalyzer (Agilent Technologies, Santa
Clara, California). RNA was not globin reduced since our pre-
liminary data showed that although globin reduction in-
creased the sensitivity, it altered the expression of nonglobin
transcripts in a nonreproducible manner (data not shown). Two
hundred fifty nanograms of total RNA were reverse tran-
scribed to complementary DNA, converted to complementary
RNA, and biotin labeled using the Ambion kit (AMIL1791; Ap-
plied Biosystems). Seven hundred fifty nanograms of comple-
mentary RNA were hybridized to Illumina HT-12 version 3.0
arrays (Illumina, San Diego, California) and incubated over-
night (16 hours) at 55°C. Arrays were washed, stained with Cy3-
labeled streptavidin, dried, and scanned on the Illumina Bead-
Scan confocal laser scanner.
Quantitative Polymerase Chain Reaction Procedures
For validation and replication of the results, complementary
DNA was synthesized from 200 ng of total RNA using Super-
script II Reverse Transcriptase (Invitrogen, Darmstadt, Ger-
many). Quantitative polymerase chain reaction (qPCR) was per-
formed using the Universal Probe Library for FKBP5, IL18R1,
and TBP on the Roche LightCycler 480 (Roche Applied Sci-
ence, Penzberg, Germany). Assays were designed using Probe
Finder Software (Roche Applied Science) and run in duplicate
according to the manufacturer’s protocol, except for a total re-
action volume of 10 µL (eTable 2).
STATISTICAL ANALYSIS
Microarray Data Analysis
Raw microarray scan files were exported using the Illumina
BeadStudio program and loaded into R for downstream
analysis (http://www.R-project.org). The data were trans-
formed and normalized using the variance-stabilizing normal-
ization.34 Of 48 804 probes present on the Human HT-12 ver-
sion 3.0 assays, probes were selected that fulfilled the criteria
of the Illumina probe detection P value of .01 in 5% of the
individuals. A total of 15 583 probes passing the filter criteria
were used for subsequent analysis. Association analysis was per-
formed in R. General linear models were constructed using the
quantitative PSS scores, rs9296158 A carrier genotypic model,
and interactions between the 2 as predictors, controlling for
age and sex. The significance of association was estimated by a
2-tailed P value corresponding to the t ratio based on a t ref-
erence distribution. To assess the contributions of model co-
variates, pairwise comparison between the full and reduced mod-
els was performed using an analysis of varianceF test. The results
were corrected for multiple testing using the permutation of
regressor residuals test implemented in the R package glmperm
(http://cran.r-project.org/web/packages/glmperm/index
.html). For each transcript, 10 000 permutations were per-
formed. The permutation of regressor residuals test permutes
the residuals from the linear regression models using the
shuffle-Z method for permutation.35 Repeated-measures analy-
sis was performed in SPSS (SPSS Inc, Chicago, Illinois) using
the analysis of variance design. The Huynh-Feldt method was
applied to correct for potential violations of the sphericity as-
sumption.36
The BiblioSphere data mining software from Genomatix was
used for pathway analysis of transcripts.37 BiblioSphere is a data-
mining solution for extracting and studying gene relation-
ships from literature databases and genome-wide promoter
analysis.38 The signal transduction association filter with the
highest specificity was used where 2 genes were co-cited in a
sentence containing a pathway-associated term, with at least 1
of the co-cited genes bearing a Genomatix signal transduction
pathway annotation used for the pathway (http://www
.genomatix.de). The JASPAR CORE database via the cREMaG
interface (http://149.156.177.116/cremag/) was used to assess
the distribution of steroid receptor binding sites.39
qPCR Data Analysis
Raw data from the Roche LightCycler 480 System were ex-
tracted using LinRegPCR software.40 The crossing thresholds
(CT) from the technical replicates were averaged across all
samples. The transcripts were normalized to housekeeping gene
TBP. NormalizedCT values were converted into the linear form
by 2-CT transformation.41 The transformedCT values were re-
gressed against the PSS score, rs9296158, and their interac-
tion, while adjusting for age and sex, in R. For calculation of
correlations between expression and PSS scores, negative cor-
relations of the CT were used to make the direction of effect
comparable with the microarray data.
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RESULTS
DESCRIPTIVE ANALYSIS OF INDIVIDUALS
USED FOR ENDOCRINE ANALYSIS
AND MICROARRAY ANALYSIS
Phenotypic characteristics of the 211 individuals used for
endocrine analysis and 111 individuals used for micro-
array analysis are shown in Table 1. For comparisons,
individuals were separated into groups of PTSD and non-
PTSD based on DSM-IV criteria for PTSD using the re-
sponses to the PSS interview.
No differences in age, sex, ethnicity, and substance
abuse were observed between the groups (P .05) in both
samples. There were no significant differences in adult
trauma exposure (P=.11) in the microarray data set, but
there was a significant difference in the endocrine data
set (P=.001). Differences in child abuse were signifi-
cant (P .001 for the endocrine data set; P=.004 for the
microarray data set). The severity of the PTSD symp-
toms measured by the PSS and current CAPS was sig-
nificantly higher among individuals in the PTSD group
(P .001 for PSS score and P .001 for CAPS score in
the endocrine data set; P .001 for PSS score and P .001
for CAPS score in the microarray data set). Individuals
with PTSD had higher Beck Depression Inventory scores
than those without PTSD (P .001 for the endocrine data
set and P .001 for the microarray data set). To deter-
mine whether the comorbidity between PTSD and de-
pression would lead to multicollinearity, diagnostic tests
for variance inflation factor and tolerance were esti-
mated using SPSS. The variance inflation factor was 1.1
and the tolerance was 0.903, indicating no evidence for
multicollinearity.
BASELINE CORTISOL LEVEL
AND DEXAMETHASONE SUPPRESSION
IN THE ATLANTA COHORT
Previously,wereportedapossiblegenotype-dependentdif-
ferenceintheeffectsofPTSDonGRsensitivity(n=80),with
higher GR sensitivity only in patients with PTSD carrying
Table 1. Comparison of 211 Individuals Used for Endocrine Analysis and 111 Individuals Used for Microarray Analysisa
Endocrine Analysis
(n=211)
Microarray Analysis
(n=111)
Mean (SD)
P Value
Mean (SD)
P Value
Non-PTSD
(n=136)
PTSD
(n=75)
Non-PTSD
(n=70)
PTSD
(n=41)
Age, y 43.28 (13.86) 40.12 (12.72) .10 44.24 (13.24) 40.66 (12.72) .17
Sex, No. (%)
M 45 (33.1) 22 (29.3)
.34
21 (30.4) 11 (27.5)
.45
F 91 (66.9) 53 (70.7) 49 (69.6) 30 (72.5)
Ethnicity, No. (%)
African American or black 123 (90.4) 67 (89.3)
.80
64 (91.42) 35 (85.37)
.44
White 8 (5.9) 6 (8) 3 (4.29) 0
Hispanic or Latino 2 (1.5) 0 1 (1.4) 4 (9.75)
Mixed 2 (1.5) 1 (1.3) 1 (1.4) 2 (4.88)
Unknown 1 (0.7) 1 (1.3) 1 (1.4) 0
Trauma exposure
TEI total trauma adult score 5.34 (3.9) 7.15 (3.58) .001 3.0 (2.0) 4.0 (2.0) .11
CTQ total score 39.03 (14.27) 49.96 (22.67) .001 39.18 (14.66) 49.58 (19.00) .004
PSS total score 5.74 (5.93) 26.17 (9.85) .001 6.70 (6.69) 25.17 (9.70) .001
CAPS current trauma total score 24.53 (27.54) 68.50 (46.91) .001 25.78 (29.62) 67.89 (44.93) .001
CAPS lifetime trauma total score 59.2 (46.13) 106.43 (53.99) .001 64.90 (46.53) 109.46 (51.73) .001
BDI total score 9.82 (8.8) 22.69 (11.98) .001 10.49 (9.27) 22.72 (11.52) .001
Substance abuse current, No. (%)
Yes 3 (2.2) 5 (6.7)
.11
23 (32.9) 17 (41.5)
.56
No 131 (97.8) 70 (93.3) 47 (67.1) 24 (58.5)
Substance abuse past, No. (%)
Yes 41 (30.8) 31 (41.3)
.09
3 (4.3) 4 (9.8)
.40
No 92 (69.2) 44 (58.7) 67 (95.7) 37 (90.2)
KMSK alcohol current score 2.6 (3.7) 2.54 (3.5) .93 2.5 (3.4) 1.87 (3.38) .60
KMSK tobacco current score 1.79 (3.3) 3.21 (3.9) .12 1.72 (3.4) 3.18 (4.1) .27
KMSK cocaine current score 0.09 (0.61) 0.83 (2.7) .10 0.22 (0.94) 0 .37
KMSK marijuana current score 1.0 (2.49) 1.0 (2.4) .99 1.056 (2.69) 1.067 (2.46) .99
Day 1 cortisol level, µg/dL 15.37 (7.70) 15.61 (7.59) .51 14.92 (7.61) 15.59 (7.47) .65
Day 2 cortisol level, µg/dL 4.94 (6.01) 4.35 (4.77) .59 4.97 (5.50) 5.46 (5.54) .44
Abbreviations: BDI, Beck Depression Inventory; CAPS, Clinician-Administered PTSD Scale; CTQ, Childhood Trauma Questionnaire;
KMSK, Kreek-McHugh-Schluger-Kellogg Scale; PSS, PTSD Symptom Scale; PTSD, posttraumatic stress disorder; TEI, Trauma Events Inventory.
SI conversion factor: To convert cortisol to nanomoles per liter, multiply by 27.588.
aPhenotypic group comparisons between individuals in the PTSD and non-PTSD groups using the proxy PTSD variable among individuals used in the
endocrine analysis (n=211) and individuals used in the microarray analysis (n=111). Group comparisons were calculated using analysis of variance, 2 test, or
Fisher exact test.
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the risk allele.10 We now reinvestigated the effects of both
PTSDsymptomsandrs9296158genotypeinasecondlarger
independent sample (n=211 for baseline cortisol level and
n=115 for the dexamethasone suppression test).
Baseline Cortisol Level
We first regressed baseline cortisol levels against the PSS
score, FKBP5 SNP rs9296158 A carrier status, and their
interaction term, adjusting for age and sex. Significant
main effects of PSS scores (P= .003) and rs9296158
(P= .007) and significant interaction between the 2
(P=.002) on baseline cortisol levels were observed. Post-
traumatic stress disorder symptom severity was nega-
tively correlated with baseline cortisol level only in
individuals carrying rs9296158 GG (Pearson correla-
tion=−0.328 for GG and 0.157 for AA/AG, both signifi-
cant at P=.01) (Figure 1A). The association remained
significant after correcting for possible confounding ef-
fects of child abuse and adult trauma severity (PSS scores:
P=.03; rs9296158: P=.04; and PSS scorers9296158:
P=.02). Overall, FKBP5 genotype was not associated with
the level of child abuse (P=.55).
Dexamethasone Suppression Test
Using repeated-measures analysis of variance, we next in-
vestigated the interaction of rs9296158 A carrier status and
PTSD status on cortisol suppression. We confirmed a sig-
nificant triple interaction of the genotype and PTSD on the
change in cortisol levels (P=.03; F114,1=4.963).
We observed a significant PTSD statusrs9296158
genotypecarrierstatusinteraction(P=.04),butnomaingeno-
type or disease effect, on the change in cortisol levels. As
observedbefore,PTSDwasassociatedwith increaseddexa-
methasonesuppressiononlyinriskalleleAcarriers.Thetriple
interactionof thegenotypeandPTSDstatusoncortisol sup-
pressionremainedsignificantafteradjusting forchildabuse
and adult trauma (P=.04) (Figure 1B).
MAIN EFFECTS OF PTSD SYMPTOM
SEVERITY ON GENE EXPRESSION
IN THE ATLANTA COHORT
To analyze the effects of PTSD symptom severity on gene
expression, the continuous PSS scores were regressed
against the filtered 15 583 expression profiles. After age
and sex adjustment and multiple testing correction using
the permutation of regressor residuals, 183 transcripts
were significant with P values.01, none of which had
been previously reported to be associated with PTSD. Of
these, 85 transcripts remained significant after adjust-
ing for possible confounding effects of child abuse and
adult trauma (eTable 3 and eFigure 2).
INTERACTION OF FKBP5 SNP rs9296158
WITH PTSD SYMPTOM SEVERITY ON GENE
EXPRESSION IN THE ATLANTA COHORT
To investigate whether the observed FKBP5 genotype-
dependent difference in GR sensitivity in PTSD would
influence gene expression patterns, we used linear re-
gression analyses to test the contribution of the continu-
ous PTSD symptom severity, rs9296158 A carrier status,
and their interaction to expression levels. Forty-one tran-
scripts were significant for the genotypePTSD symp-
tom interaction after correcting for multiple testing using
the permutation of regressor residuals test and an inter-
action P value of .05 (Table 2 and eFigure 3). Nine
of these 41 transcripts had already been identified using
only PTSD symptoms as a predictor as described earlier,
so that 32 novel transcripts were identified using this
model. These 32 genes includedFKBP5 and IL18R1, where
either the molecule itself or the ligand had previously been
reported to be regulated by PTSD.42-44
Pathway Analysis
Analysis of gene expression data in the form of gene net-
works can provide a more comprehensive view of gene
interactions underlying complex traits of interest.45 To
investigate possible common components of regulatory
pathways, the 41 transcripts were characterized using the
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Figure 1. Cortisol levels at baseline and after low-dose dexamethasone
suppression. A, Baseline cortisol levels in individuals with and without
posttraumatic stress disorder (PTSD) stratified by the rs9296158 A carrier
status. In individuals carrying rs9296158 GG, PTSD symptom severity was
negatively correlated with baseline cortisol level (Pearson
correlation=−0.328), and in individuals carrying AA/AG, PTSD symptom
severity was positively correlated with baseline cortisol level (Pearson
correlation=0.157). B, Levels of serum cortisol suppression after low-dose
(0.5-mg) dexamethasone suppression in individuals with and without PTSD
stratified by rs9296158 A carrier status. Posttraumatic stress disorder was
associated with increased dexamethasone suppression only in risk allele A
carriers. The triple interaction of rs9296158 A carrier status and PTSD status
on cortisol suppression was significant (P=.03). To convert cortisol to
nanomoles per liter, multiply by 27.588.
ARCH GEN PSYCHIATRY/ VOL 68 (NO. 9), SEP 2011 WWW.ARCHGENPSYCHIATRY.COM
905
©2011 American Medical Association. All rights reserved.
Downloaded From: http://archpsyc.jamanetwork.com/ by a UQ Library User  on 09/13/2015
BiblioSphere software.37 Pathway analysis of these 41 tran-
scripts revealed a network that directly included 15 of
the tested genes as well as associated transcription fac-
tors. These included CREB1, HDAC1, FOS, and STAT5B,
which had previously been reported to be associated with
PTSD symptoms42,43 (eFigure 4). In fact, STAT5B expres-
sion showed a significant correlation with FKBP5 ex-
pression in this data set, with a Pearson correlation of
0.25 and 2-tailed significance of P=.007.
Analysis of Transcription Factor Binding Sites
We next investigated the distribution of steroid hor-
mone biding sites, including GR response elements, an-
drogen receptor response elements, and progesterone re-
ceptor response elements, within the 32 transcripts
regulated by the SNPPTSD symptom interaction vs the
183 transcripts associated with PTSD symptom severity
alone. For this, the JASPAR CORE database was probed
to test for a possible overrepresentation of these steroid
receptor response elements. Comparisons between the
183 transcripts identified using the PTSD symptom scores
and 32 transcripts significant for the rs9296158PSS
score interaction revealed a highly significant overrep-
resentation of steroid response elements (GR response
elements and androgen receptor response elements)
among the 32 transcripts but not the 183 transcripts as-
sociated with PTSD symptom severity alone (eTable 4).
Table 2. List of 41 Transcripts Significant for the Interaction Between PSS Score and rs9296158a
Gene Symbol
Illuminab
Probe ID
Significant
With PSS
Score Alone
Expression~PSS Score Pearson r PSS Score rs9296158 P Value
rs9296158 GG rs9296158 AA/AG ANOVA
Trauma
Adjusted Corrected
P76 ILMN_1734184 No 0.47817 −0.33669 .00015 .00043 .00020
TK2 ILMN_1766814 No −0.76436 −0.02777 .00016 .00028 .00010
CTSC ILMN_1696347 No 0.61956 −0.09383 .00031 .03900 .00020
ODF2 ILMN_1730698 No 0.49463 −0.14273 .00073 .09206 .00150
GTPBP2 ILMN_1694475 No −0.59951 0.10253 .00081 .02476 .00070
LOC643452 ILMN_1682736 No −0.56890 0.09748 .00086 .05438 .00130
FKBP5 ILMN_1778444 No −0.49987 0.02563 .00282 .04444 .00330
BIRC5 ILMN_2349459 No 0.57429 0.05468 .00355 .03030 .00450
MCM4 ILMN_2412860 Yes 0.50162 −0.03105 .00381 .03824 .00340
C3orf1 ILMN_2193175 No −0.33791 0.30346 .00396 .07704 .00450
EZH2 ILMN_1708105 No 0.50143 −0.11772 .00488 .28239 .00480
ZBTB16 ILMN_2305407 No −0.53328 −0.04405 .00673 .02190 .00720
BHLHB2 ILMN_1768534 No 0.35849 −0.18584 .00696 .13020 .00610
LOC647460 ILMN_1729198 No −0.35417 0.30213 .00702 .02798 .00670
FAM69A ILMN_1682577 No −0.39838 0.22979 .00829 .05197 .00850
C14orf80 ILMN_1653553 No 0.53635 0.06719 .00975 .12307 .01200
ZNF684 ILMN_1751393 No −0.26585 0.24363 .01053 .20257 .01420
CAMK1D ILMN_1795561 Yes 0.19985 −0.37048 .01070 .02572 .01150
GINS2 ILMN_1809590 Yes 0.61090 0.18267 .01118 .00738 .01220
ACOT7 ILMN_1740265 No 0.65108 0.07385 .01519 .02759 .01630
LOC647037 ILMN_1761922 No −0.18321 0.31981 .01595 .08595 .01530
NUSAP1 ILMN_1726720 Yes 0.53809 0.13494 .01635 .03178 .01580
THAP11 ILMN_1780699 No 0.23107 −0.27642 .02019 .05254 .02370
FAM108B1 ILMN_1660440 No −0.38296 0.00115 .02032 .00046 .02090
BZW1 ILMN_1793846 No −0.13509 0.33007 .02387 .05116 .02280
NXF1 ILMN_2358652 Yes 0.11059 −0.34754 .02648 .03248 .02530
PLA2G4C ILMN_1810191 No 0.32896 −0.08184 .02707 .01867 .02710
UGP2 ILMN_2284181 No −0.29111 0.32012 .02744 .04307 .03020
CDC20 ILMN_1663390 Yes 0.54947 0.14556 .02830 .02563 .02590
PLAGL2 ILMN_1786601 No 0.44579 −0.13340 .02920 .01518 .03030
CASZ1 ILMN_1655191 Yes 0.59386 0.16751 .03004 .13843 .03150
CX3CR1 ILMN_1745788 No 0.54696 0.04575 .03028 .06447 .02790
POLDIP3 ILMN_1685845 No −0.46645 −0.00050 .03377 .07222 .03100
ZBTB16 ILMN_2402817 No −0.45215 −0.08603 .03660 .00956 .03660
SLC25A43 ILMN_1662097 No −0.28835 0.12678 .03810 .04372 .04030
ASPM ILMN_1815184 No 0.42272 −0.03327 .03870 .40102 .04000
NCOA6IP ILMN_1651506 Yes 0.04771 0.40608 .04086 .00212 .04030
SLC8A3 ILMN_1712023 Yes −0.09220 −0.40295 .04144 .08910 .04210
GCLM ILMN_1788547 No 0.13927 −0.24781 .04240 .01150 .04300
CCNF ILMN_1773119 No 0.57323 0.05194 .04625 .16164 .04220
IL18R1 ILMN_1781700 No −0.33430 −0.06447 .04906 .07070 .05000
Abbreviations: ANOVA, analysis of variance; PSS, PTSD Symptom Scale; ~, described by.
aList of 41 transcripts significant for the interaction between PSS score and rs9296158 after adjusting for age and sex. The transcripts were corrected for
multiple testing using the permutation of regressor residuals test. The Pearson correlation coefficient between the transcript expression levels and the continuous
PSS score is indicated across all individuals stratified by the rs9296158 A carrier status groups.
b Illumina, San Diego, California.
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No progesterone receptor response elements were pre-
dicted in any of the tested transcripts.
qPCR VALIDATION OF FKBP5
AND IL18R1 EXPRESSION
Because FKBP5 and IL18 had been reported in previous
PTSD gene expression studies, we proceeded to validate
FKBP5 and IL18R1 expression results in the 111 indi-
viduals from the microarray analysis using qPCR. For both
FKBP5 and IL18R1, significant main effects for PSS score
as well as significant interaction between PSS and
rs9296158 were observed (FKBP5: PSS total score,
P=.002552; PSS scorers9296158, P=.006932; IL18R1:
PSS total score, P= .012253; PSS score rs9296158,
P=.018549) in the qPCR data set.
qPCR REPLICATION OF FKBP5
AND IL18R1 EXPRESSION
Next, we proceeded to replicate our findings in an addi-
tional set of 98 individuals not used in the microarray analy-
sis. We replicated the significant main effects for PSS score
as well as the significant interaction between the 2 forFKBP5
and IL18R1 after adjusting for age and sex in the indepen-
dent replication sample (FKBP5: PSS total score,P=.01967;
PSS scorers9296158,P=.00319; IL18R1: PSS total score,
P=.03826; PSS scorers9296158, P=.00408).
The genotype-dependent differences in correlation of
FKBP5 messenger RNA levels and PSS score severity in
the microarray data set, the qPCR validation, and the rep-
lication data set are depicted in Figure 2.
COMMENT
These data from endocrine measures as well as gene ex-
pression profiling suggest that the functional FKBP5 poly-
morphism rs9296158 is not only associated with an in-
creased risk for PTSD following childhood trauma10,11 but
might also define biologically distinct subtypes of this dis-
order. Endocrine measures and gene expression data were
available in more than 200 traumatized individuals. In fact,
we could replicate that only risk allele carriers of this SNP
show the previously reported association of GR supersen-
sitivity with PTSD.10,13 On the other hand, baseline corti-
sol levels were decreased in PTSD only in patients with the
nonrisk GG genotype. This suggests that the inheritance
of GR sensitivity–moderating FKBP5 polymorphisms10,22
can determine specific types of HPA-axis dysfunction within
PTSD that were also reflected in gene-expression changes
of a subset of GR-responsive genes.
A number of studies have reported both decreased base-
line cortisol levels as well as increased GR sensitivity46
in patients with PTSD, although the findings are not uni-
formly consistent across studies.14,17,47 While we also ob-
served these 2 endocrine features with PTSD, these find-
ings are restricted to specificFKBP5 SNP genotype groups,
which might be an explanation for some of the incon-
sistent findings in the literature. In this article, we rep-
licated a relative GR resistance in nonaffected individu-
als carrying the risk allele, which is in line with our
previous report.10 These data also support the previ-
ously reported decrease in negative feedback capacity in
these individuals.23 Also, as previously reported, the geno-
type-dependent association with GR function seems to
be state dependent, with increased GR sensitivity in risk
allele carriers with PTSD. We are currently investigat-
ing the molecular basis of this state dependence and specu-
late that in addition to possible expression changes of other
GR chaperones and other systems influencing the HPA
axis, this might be mediated by epigenetic changes. In-
terestingly, the protective genotype, not the risk, was as-
sociated with decreasing baseline cortisol levels with in-
creasing PTSD symptoms. In our sample, decreased
baseline cortisol level and increasing GR sensitivity there-
fore do not seem to be strongly correlated, suggesting that
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Figure 2. Validation and replication of FKBP5 expression differences in posttraumatic stress disorder (PTSD) using quantitative polymerase chain reaction
(qPCR). The PTSD Symptom Scale (PSS) total scores are plotted on the x-axis against the expression levels as measured by log2 expression for the microarray
data and 2-CT (change in crossing thresholds) for the qPCR validation and replication on the y-axis. The Pearson correlation coefficients for the rs9296158 A
carrier status groups are shown. Post hoc genotype-dependent differences of the correlation coefficients were established by converting them into Fisher
z scores.10 The z score differences between the 2 genotype groups were significant for the microarray expression (z=2.17; significant at P=.01), qPCR validation
(z=2.12; significant at P=.05), and qPCR replication (z=2.87; significant at P=.01). RT-PCR indicates reverse transcriptase–polymerase chain reaction.
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other mechanisms besides efficiency of negative feed-
back of the HPA axis, possibly including stress reactiv-
ity, regulate baseline cortisol levels in PTSD. The possi-
bility that these 2 measures are somewhat disjunct is also
supported by the fact that while the finding of increased
GR sensitivity is relatively consistent across studies, it is
less so for baseline cortisol changes, with decreases, no
changes, and increases reported in PTSD.16,48 A previ-
ous study had also reported that PTSD-related de-
creases in baseline cortisol level might be dependent on
a functional GR polymorphism, a possible additional con-
founder in this association.49
The genotype-dependent endocrine differences with
PTSD symptoms were also paralleled by genotype-
dependent differences in whole-blood gene expression pat-
tern, where expression levels of 183 transcripts were sig-
nificantly associated with PTSD symptoms alone. Within
these, none had been previously identified to be associ-
ated with PTSD. Adding the FKBP5 polymorphism to the
model identified 32 transcripts not detected in the first
model that showed a significant interaction betweenFKBP5
genotype and PTSD symptom severity. In fact, these tran-
scripts showed strong genotype-dependent differences for
the correlation of gene expression levels with PTSD symp-
tom severity (eFigure 3), which likely has precluded their
identification when analyzing the association with PTSD
symptom severity alone. Among the top transcripts exhib-
iting the most significant gene expression interaction ef-
fects wasFKBP5 itself. This is not surprising given the pre-
viously discussed influence of PTSD and FKBP5 on GR
function and the fact that FKBP5 appears to be one of the
most sensitive readouts of GR stimulation.FKBP5has been
shown to be one of the genes with the strongest induction
by GR activation in a number of studies, including our
own.50,51 Most notably, Yehuda and colleagues43 have also
described a downregulation of FKBP5 gene expression in
whole blood with PTSD, as we observed for rs9296158 GG
carriers. Within these 32 genes, the IL18R1 transcript is also
an interesting candidate. Zieker et al44 reported interleu-
kin 18 to be differentially expressed in the peripheral blood
of patients with PTSD, concordant with the differential regu-
lation of its receptor IL18R1 in our cohort.
We also found that 15 of the genes regulated by the in-
teraction between FKBP5 genotype and PTSD can be in-
tegrated into the same pathway (eFigure 4) using the Bib-
lioSphere software.37 When expanding the annotation to
include related transcription factors, we identified an-
other 4 previously reported PTSD candidates:CREB1,FOS,
HDAC1, and STAT5B42,43 to be part of this common regu-
latory pathway. We could confirm the significant correla-
tion between expression levels of FKBP5 and STAT5B in
this study, both of which had been previously shown to
be regulated with PTSD by Yehuda et al.43 Our data sug-
gest that a data mining approach could be informative in
revealing coexpressed gene networks and might help iden-
tify transcripts that otherwise would be missed when not
passing statistical thresholds of significance because of the
subtle gene expression differences.
While we did identify a number of genes regulated by
PTSD symptom severity itself, our data suggest that a net-
work of genes is differentially regulated depending on
FKBP5 genotype and related differences in GR sensitiv-
ity. In fact, there was a significant overrepresentation of
GR response elements and androgen receptor response
elements among these 32 transcripts significant for the
interaction term compared with the 183 genes regu-
lated by PTSD alone. Altogether, these findings suggest
that the combined model of FKBP5 SNP genotype and
PTSD symptoms seems most relevant for GR-
dependent transcripts, while other predictive models
might be necessary to capture differences in the expres-
sion of other gene classes.
While we were able to replicate some of the genes and
pathways identified in previous studies, others could not
be replicated. This is likely because of a number of rea-
sons, including false-positive and false-negative associa-
tions in either study, differences in clinical study de-
sign, sample characteristics, type of microarrays, and
statistical analysis.
A strength of our microarray gene expression study
(n=111 in total) is the large sample size, with 41 individu-
als with a probable PTSD diagnosis, which, to our knowl-
edge, is larger than any of the previously reported expres-
sion array studies for this disorder. In the overall sample,
we investigated 75 individuals with a probable PTSD di-
agnosis. We acknowledge that our main PTSD definition
is symptom driven; using the PSS might have included in-
dividuals with other anxiety disorders also showing high
PSS scores.52 However, about 70% of our cohort had CAPS-
based current PTSD diagnoses and these concorded well
with the PSS scores (Pearson r=0.657, significant at a
P=.01). The use of the PSS allowed us to include all indi-
viduals and to increase the power of the study by using a
quantitative predictor vs using diagnostic cutoffs, a strat-
egy now advocated by a number of investigators for bio-
marker discovery.42,53 A limitation of this highly trauma-
tized sample is the heterogeneity regarding the timing of
the trauma as well as the types of traumatic events. De-
spite this, our gene expression results appear to be com-
parable with other studies with much more defined index
trauma, as described earlier.16,42
In this sample, all subjects had experienced at least 1
significant trauma; nonetheless, we noted significant dif-
ferences in overall trauma exposure as well as the level of
child abuse between individuals with high vs low PTSD
symptoms. When correcting the analysis for adult trauma
and child abuse exposure, about 50% of the associations
with PTSD severity alone remained significant at a level of
P=.05, indicating the importance of increased trauma ex-
posure on gene expression, even when using traumatized
individuals as controls (eTable 3). Differences in severity
and timing of trauma exposure might also account for the
slight differences in the PTSDSNP interaction onFKBP5
messenger RNA expression in the discovery vs the repli-
cation sample (Figure 2 and eTable 1).
Independent replication is extremely important to as-
sess the validity of gene expression findings, because more
often than not specific changes reported for psychiatric
disorders could not be replicated.54,55 In this study, we
chose FKBP5 and IL18R1 for validation and replication,
because they had previously been implicated in this dis-
order. We could, in fact, validate and replicate the asso-
ciation with genotype-dependent gene expression dif-
ferences of both 2 transcripts using qPCR.
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In summary, using a large sample of 219 traumatized
individuals, we examined the effects of FKBP5 rs9296158
genotype, previously reported to increase the risk for PTSD
with early trauma, on putative biomarkers for this dis-
order. In this study, we found that rs9296158 may be used
to identify biologically different subtypes of PTSD in that
the genotype groups differed with respect to PTSD-
related changes in GR sensitivity. This was reflected in
genotype- and PTSD-dependent differences in the ex-
pression of GR-dependent transcripts in whole blood. Our
findings support the importance of using genetic mark-
ers and biological measures to increase the predictive va-
lidity of biomarkers in psychiatric disorders.56
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